• Explore /
  • Poster
  • / CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).

CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC).

Abstract Poster

Authors

William Sikov

William M. Sikov

Women and Infants Hospital of Rhode Island, Providence, RI

William M. Sikov , Mei-Yin Polley , Erin Twohy , Charles M. Perou , Baljit Singh , Donald A. Berry , Sara M. Tolaney , George Somlo , Elisa R. Port , Cynthia X. Ma , Charles S. Kuzma , Eleftherios P. Mamounas , Mehra Golshan , Jennifer Ruth Bellon , Deborah E. Collyar , Olwen Mary Hahn , Clifford A. Hudis , Eric P. Winer , Ann H. Partridge , Lisa A. Carey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT00861705

Citation

J Clin Oncol 37, 2019 (suppl; abstr 591)

DOI

10.1200/JCO.2019.37.15_suppl.591

Abstract #

591

Poster Bd #

83

Abstract Disclosures

Similar Posters

First Author: Cheng Wang

First Author: Stephen James Luen

First Author: Roberto Antonio Leon-Ferre

First Author: Jai Min Ryu